7 recruiting, 3 completed, 2 active not recruiting, 1 not yet recruiting. 9 Phase 3, 2 Phase 1, 1 Not applicable, 1 Phase 4.
By phase and status
Follow Depemokimab: new trials by email Literature Review of Depemokimab trials Research Report on Depemokimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma Depemokimab - Allergic Bronchopulmonary Aspergillosis, ABPA Not applicable Not yet recruiting Qianfoshan Hospital 10 2026-11-01 2026-09-24 Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Depemokimab - Nasal Polyps Phase 4 Recruiting GlaxoSmithKline 28 2026-07-15 2026-09-08 A Study of Depemokimab in Participants of 6 to 11 Years of Age Depemokimab - Asthma Phase 3 Recruiting GlaxoSmithKline 34 2026-06-25 2026-08-26 A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma Depemokimab, Placebo - Asthma Phase 3 Recruiting GlaxoSmithKline 456 2026-03-13 2026-08-17 eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation Depemokimab, Placebo - Pulmonary Disease, Chronic Obstructive Phase 3 Recruiting GlaxoSmithKline 1196 2025-10-20 2026-07-28 Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) Depemokimab, Placebo - Pulmonary Disease, Chronic Obstructive Phase 3 Recruiting GlaxoSmithKline 961 2025-06-23 2026-10-05 Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation Depemokimab, Placebo - Pulmonary Disease, Chronic Obstructive Phase 3 Recruiting GlaxoSmithKline 981 2025-06-20 2026-10-05 Depemokimab Asthma Imaging and Bronchoscopy Sub-Study Depemokimab - Asthma Phase 3 Recruiting GlaxoSmithKline 150 2024-07-19 2026-07-02 A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants Depemokimab - Asthma Phase 1 Completed GlaxoSmithKline 140 2022-12-13 2026-06-16 Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial Depemokimab, Placebo - Hypereosinophilic Syndrome Phase 3 Active not recruiting GlaxoSmithKline 110 2022-09-06 2026-10-13 Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Depemokimab, Mepolizumab, Placebo matching mepolizumab - Eosinophilic Granulomatosis With Polyangiitis Phase 3 Active not recruiting GlaxoSmithKline 163 2022-07-14 2026-07-08 Study of GSK3511294 in Healthy Chinese Participants Depemokimab - Asthma Phase 1 Completed GlaxoSmithKline 20 2021-12-10 2026-05-26 A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype GSK3511294, Placebo - Asthma Phase 3 Completed GlaxoSmithKline 397 2021-02-04 2024-11-29
Conditions studied Asthma (6) · Pulmonary Disease, Chronic Obstructive (3) · Pulmonary Eosinophilia (2) · Aspergillosis, Allergic Bronchopulmonary (1) · Churg-Strauss Syndrome (1) · Hypereosinophilic Syndrome (1) · Nasal Polyps (1)
Sponsors GlaxoSmithKline (12) · Qianfoshan Hospital (1)
Countries United States (10) · China (7) · Canada (6) · Germany (6) · Japan (6) · Spain (6) · United Kingdom (6) · Italy (5) · Poland (5) · Argentina (4) · Australia (4) · France (4) · South Korea (4) · Czechia (3) · Greece (3)
Results publications PMID 41461999 , PMID 41868651
NIH funding 2023 (2), 2025 (2)